Skip to main content

Advertisement

SpringerLink
Log in

The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Introduction

The aim of this study is to evaluate the correlation of the serum neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and mean platelet volume (MPV), with the standardized uptake value (SUVmax), and metabolic tumor volume (MTV) in F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patient with esophageal squamous cell cancer at baseline.

Methods

PET/CTs were performed in 52 patients with esophageal squamous cell cancer, making up the patient group. An additional 52 patients who underwent endoscopy due to dyspepsia with normal esophagus (as a control group) were included in the study to compare the hematological parameters between the patient groups.

Results

The median age was 60.0 ± 12.8 years (range 39–84 years) for the patients with esophageal cancer, and 56.9 ± 12.3 years for the control group. Statistical differences were found in terms of the neutrophils, lymphocytes, NLR, PLT, PLR, and MPV between the patients with esophageal cancer and the control group. In the correlation analysis, only the NLR was correlated with the MTV for all of the patients (p = 0.013, r = 0.344). The SUVmax was not correlated with these hematological parameters.

Conclusion

At baseline neutrophil-to-lymphocyte ratio is associated with the metabolic tumor volume, which was assessed using the PET/CT in patients with esophageal squamous cell cancer. The SUVmax values were not related to these parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  3. Stavrou EP, McElroy HJ, Baker DF, Smith G, Bishop JF. Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005. Med J. 2009;191:310–4.

    Google Scholar 

  4. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;19(12):58.

    Article  Google Scholar 

  5. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.

    Article  PubMed  Google Scholar 

  6. Yang X, Huang Y, Feng JF, Liu JS. Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: a meta-analysis. Onco Targets Ther. 2015;10(8):789–94.

    Article  Google Scholar 

  7. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362–9.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Duan H, Zhang X, Wang FX, Cai MY, Ma GW, Yang H, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. World J Gastroenterol. 2015;21(18):5591–7.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2014. doi:10.1111/dote.12296.

  10. Kılınçalp S, Ekiz F, Başar O, Ayte MR, Coban S, Yılmaz B, et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets. 2014;25(8):592–4.

    Article  PubMed  Google Scholar 

  11. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.

    Article  CAS  PubMed  Google Scholar 

  12. Lee Y, Kim SH, Han JY, Kim HT, Yun T, Lee JS. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012;138(12):2009–16.

    Article  CAS  PubMed  Google Scholar 

  13. De Larco JE, Wuertz BRK, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:4895–900.

    Article  PubMed  Google Scholar 

  14. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–39.

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, et al. Involvement of proinflammatory cytokines IL-1β and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005;25(2A):709–13.

    CAS  PubMed  Google Scholar 

  16. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis. 2010;30(3):251–62.

    Article  CAS  PubMed  Google Scholar 

  17. Ji WH, Jiang YH, Ji YL, Li B, Mao WM. Prechemotherapy neutrophil: lymphocyte ratio is superior to the platelet: lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy. Dis Esophagus. 2015. doi:10.1111/dote.12322.

    PubMed  Google Scholar 

  18. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21:1008–15.

    Article  PubMed  Google Scholar 

  19. Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2008–16.

    Article  CAS  PubMed  Google Scholar 

  20. Liu Q, Fu XL, Yu W, Zhu ZF, Zhang YJ. Potential values of metabolic tumor volume and heterogeneity measured with 18F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy. Nucl Med Commun. 2015;36(5):423–9.

    PubMed  Google Scholar 

  21. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200–7.

    Article  CAS  PubMed  Google Scholar 

  22. Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, et al. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):858–67.

    Article  CAS  PubMed  Google Scholar 

  23. Fathinul Fikri AS, Dharmendran R, Vikneswaran P, Nordin AJ. 18F-FDG PET/CT as a potential predictor of survival in patient with oesophageal cancer: a preliminary result. Abdom Imaging. 2015. doi:10.1007/s00261-014-0343-2.

    PubMed  Google Scholar 

  24. Lindner K, Palmes D, Senninger N, Hummel R. PET/CT predicts survival in patients undergoing primary surgery for esophageal cancer. Langenbecks Arch Surg. 2015;400(2):229–35.

    Article  PubMed  Google Scholar 

  25. Jeon HW, Kim KS, Sung SW, Park HJ, Kim YD, Park JK. Prognostic value of the maximum standardized uptake value on positron emission tomography for esophageal squamous cell carcinoma. Thorac Cardiovasc Surg. 2015;63(4):341–8.

    Article  PubMed  Google Scholar 

  26. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, et al. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009;115(3):508–16.

    Article  PubMed  Google Scholar 

  27. Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86(4):1131–8.

    Article  PubMed  Google Scholar 

  28. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191–202.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, School of Medicine, Yüzüncü Yıl University, Van, Turkey

    Erdem Sürücü & Yusuf Demir

  2. Department of Nuclear Medicine, School of Medicine, Pamukkale University, Denizli, Turkey

    Tarık Şengöz

Authors
  1. Erdem Sürücü
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuf Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tarık Şengöz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erdem Sürücü.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sürücü, E., Demir, Y. & Şengöz, T. The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. Ann Nucl Med 29, 906–910 (2015). https://doi.org/10.1007/s12149-015-1020-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-015-1020-4

Keywords

Search

Navigation